Table 1.
Characteristics of the Prospective Family Study Cohort by quintiles of recreational physical activity (n = 4610)
| Characteristic | Q1 <4 MET-hrs/wk |
Q2 4-11 MET-hrs/wk |
Q3 12-20 MET-hrs/wk |
Q4 21-34 MET-hrs/wk |
Q5 >34 MET-hrs/wk |
|---|---|---|---|---|---|
| Total No. of women | 857 | 910 | 1193 | 781 | 869 |
| Age at first invasive BC diagnosis, No. (%), y | |||||
| <40 | 158 (18.4) | 194 (21.3) | 245 (20.5) | 195 (25.0) | 264 (30.4) |
| 40-49 | 269 (31.4) | 316 (34.7) | 379 (31.8) | 238 (30.5) | 276 (31.8) |
| 50-59 | 304 (35.5) | 279 (30.7) | 408 (34.2) | 237 (30.3) | 227 (26.1) |
| ≥60 | 126 (14.7) | 121 (13.3) | 161 (13.5) | 111 (14.2) | 102 (11.7) |
| Year of birth, No. (%) | |||||
| <1950 | 435 (50.8) | 414 (45.5) | 580 (48.6) | 353 (45.2) | 332 (38.2) |
| 1950-1959 | 263 (30.7) | 292 (32.1) | 364 (30.5) | 242 (31.0) | 263 (30.3) |
| 1960-1969 | 133 (15.5) | 178 (19.6) | 206 (17.3) | 156 (20.0) | 224 (25.8) |
| ≥1970 | 26 (3.0) | 26 (2.9) | 43 (3.6) | 30 (3.8) | 50 (5.8) |
| Race and ethnicity, No. (%) | |||||
| Asian | 158 (18.4) | 107 (11.8) | 133 (11.1) | 68 (8.7) | 55 (6.3) |
| Hispanic | 104 (12.1) | 134 (14.7) | 134 (11.2) | 70 (9.0) | 131 (15.1) |
| Non-Hispanic Black | 57 (6.7) | 41 (4.5) | 191 (16.0) | 109 (14.0) | 44 (5.1) |
| Non-Hispanic White | 514 (60.0) | 608 (66.8) | 708 (59.3) | 522 (66.8) | 613 (70.5) |
| Other | 24 (2.8) | 20 (2.2) | 27 (2.3) | 12 (1.5) | 26 (3.0) |
| Educational attainment, No. (%) | |||||
| High school graduate/GED or less | 374 (43.6) | 299 (32.9) | 355 (29.8) | 204 (26.1) | 219 (25.2) |
| Some college/vocational school | 304 (35.5) | 346 (38.0) | 466 (39.1) | 309 (39.6) | 304 (35.0) |
| Bachelor degree or higher | 179 (20.9) | 265 (29.1) | 372 (31.2) | 268 (34.3) | 346 (39.8) |
| Body mass index, No. (%) | |||||
| <25 kg/m2 | 395 (46.1) | 424 (46.6) | 568 (47.6) | 437 (56.0) | 532 (61.2) |
| 25 to <30 kg/m2 | 237 (27.7) | 266 (29.2) | 364 (30.5) | 214 (27.4) | 226 (26.0) |
| ≥30 kg/m2 | 225 (26.3) | 220 (24.2) | 261 (21.9) | 130 (16.6) | 111 (12.8) |
| Cigarette smoking status at baseline, No. (%) | |||||
| Never | 524 (61.1) | 550 (60.4) | 718 (60.2) | 425 (54.4) | 449 (51.7) |
| Former | 197 (23.0) | 241 (26.5) | 328 (27.5) | 236 (30.2) | 312 (35.9) |
| Current | 136 (15.9) | 119 (13.1) | 147 (12.3) | 120 (15.4) | 108 (12.4) |
| Alcohol consumption at baseline, No. (%) | |||||
| Never | 560 (65.3) | 530 (58.2) | 659 (55.2) | 383 (49.0) | 388 (44.6) |
| Former | 104 (12.1) | 122 (13.4) | 150 (12.6) | 104 (13.3) | 152 (17.5) |
| Current | 193 (22.5) | 258 (28.4) | 384 (32.2) | 294 (37.6) | 329 (37.9) |
| Postmenopausal hormone therapy at baseline, No. (%) | |||||
| Never | 607 (70.8) | 671 (73.7) | 830 (69.6) | 564 (72.2) | 640 (73.7) |
| Former | 246 (28.7) | 229 (25.2) | 347 (29.1) | 203 (26.0) | 214 (24.6) |
| Current | 4 (0.5) | 10 (1.1) | 16 (1.3) | 14 (1.8) | 15 (1.7) |
| Estrogen receptor status of first invasive BC, No. (%) | |||||
| Positivea | 519 (60.6) | 549 (60.3) | 726 (60.9) | 470 (60.2) | 500 (57.5) |
| Negative | 211 (24.6) | 196 (21.5) | 322 (27.0) | 196 (25.1) | 233 (26.8) |
| Missing | 127 (14.8) | 165 (18.1) | 145 (12.2) | 115 (14.7) | 136 (15.7) |
| Tumor stage at diagnosis of first invasive BC, No. (%) | |||||
| Stage 1 | 300 (35.0) | 327 (35.9) | 451 (37.8) | 305 (39.1) | 341 (39.2) |
| Stage 2 | 285 (33.3) | 317 (34.8) | 428 (35.9) | 255 (32.7) | 292 (33.6) |
| Stage 3-4 | 52 (6.1) | 50 (5.5) | 85 (7.1) | 62 (7.9) | 35 (4.0) |
| Unknown | 220 (25.7) | 216 (23.7) | 229 (19.2) | 159 (20.4) | 201 (23.1) |
| Chemotherapy for first invasive BC, No. (%) | |||||
| No | 281 (32.8) | 314 (34.5) | 387 (32.4) | 278 (35.6) | 294 (33.8) |
| Yes | 421 (49.1) | 476 (52.3) | 662 (55.5) | 400 (51.2) | 452 (52.0) |
| Unknown | 155 (18.1) | 120 (13.2) | 144 (12.1) | 103 (13.2) | 123 (14.2) |
| Radiation for first invasive BC, No. (%) | |||||
| No | 248 (28.9) | 266 (29.2) | 328 (27.5) | 201 (25.7) | 246 (28.3) |
| Yes | 455 (53.1) | 525 (57.7) | 724 (60.7) | 475 (60.8) | 499 (57.4) |
| Unknown | 154 (18.0) | 119 (13.1) | 141 (11.8) | 105 (13.4) | 124 (14.3) |
| Surgery for first invasive BC, No. (%) | |||||
| None | 28 (3.3) | 34 (3.7) | 34 (2.9) | 31 (4.0) | 28 (3.2) |
| Mastectomy | 359 (41.9) | 361 (39.7) | 490 (41.1) | 309 (39.6) | 325 (37.4) |
| Lumpectomy | 388 (45.3) | 465 (51.1) | 589 (49.4) | 396 (50.7) | 452 (52.0) |
| Unknown | 82 (9.6) | 50 (5.5) | 80 (6.7) | 45 (5.8) | 64 (7.4) |
| Number of first- and second-degree relatives with BC, No. (%) | |||||
| 0 | 406 (47.4) | 399 (43.9) | 560 (46.9) | 353 (45.2) | 380 (43.7) |
| 1 | 260 (30.3) | 280 (30.8) | 339 (28.4) | 226 (28.9) | 269 (31.0) |
| 2 | 116 (13.5) | 149 (16.4) | 184 (15.4) | 130 (16.7) | 139 (16.0) |
| ≥3 | 75 (8.8) | 82 (9.0) | 110 (9.2) | 72 (9.2) | 81 (9.3) |
| BRCA1 or BRCA2 PVs, No. (%) | |||||
| Nob | 790 (92.2) | 846 (93.0) | 1117 (93.6) | 709 (90.8) | 774 (89.1) |
| Yesc | 67 (7.8) | 64 (7.0) | 76 (6.4) | 72 (9.2) | 95 (10.9) |
| Remaining lifetime BC risk, mean (SD) | 17.3 (17.0) | 17.8 (16.9) | 17.1 (15.4) | 19.7 (19.3) | 21.6 (20.5) |
a
Includes 49 women categorized as borderline for estrogen receptor status. BC = breast cancer; GED = general education degree; MET = metabolic equivalents; PVs = pathogenic variants.
b
Includes 3137 women who tested negative for BRCA1 and BRCA2 PVs and 1099 women without a genetic test result.
c
Includes 204 women with a BRCA1 PV, 168 women with a BRCA2 PV, and 2 women with both a BRCA1 and BRCA2 PV.